OGI vs. WEED, CPH, CRDL, HLS, ACB, GUD, DR, VHI, QIPT, and KSI
Should you be buying Organigram stock or one of its competitors? The main competitors of Organigram include Canopy Growth (WEED), Cipher Pharmaceuticals (CPH), Cardiol Therapeutics (CRDL), HLS Therapeutics (HLS), Aurora Cannabis (ACB), Knight Therapeutics (GUD), Medical Facilities (DR), Vitalhub (VHI), Quipt Home Medical (QIPT), and kneat.com (KSI). These companies are all part of the "medical" sector.
Canopy Growth (TSE:WEED) and Organigram (TSE:OGI) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
Canopy Growth received 594 more outperform votes than Organigram when rated by MarketBeat users. Likewise, 62.44% of users gave Canopy Growth an outperform vote while only 44.23% of users gave Organigram an outperform vote.
In the previous week, Canopy Growth had 1 more articles in the media than Organigram. MarketBeat recorded 4 mentions for Canopy Growth and 3 mentions for Organigram. Organigram's average media sentiment score of 0.72 beat Canopy Growth's score of 0.24 indicating that Canopy Growth is being referred to more favorably in the media.
4.9% of Canopy Growth shares are held by institutional investors. Comparatively, 11.2% of Organigram shares are held by institutional investors. 19.0% of Canopy Growth shares are held by company insiders. Comparatively, 34.7% of Organigram shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Canopy Growth has a beta of 1.63, meaning that its stock price is 63% more volatile than the S&P 500. Comparatively, Organigram has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Canopy Growth has a net margin of 0.00% compared to Canopy Growth's net margin of -153.80%. Canopy Growth's return on equity of -54.53% beat Organigram's return on equity.
Organigram has lower revenue, but higher earnings than Canopy Growth. Organigram is trading at a lower price-to-earnings ratio than Canopy Growth, indicating that it is currently the more affordable of the two stocks.
Canopy Growth currently has a consensus price target of C$3.20, suggesting a potential downside of 73.92%. Organigram has a consensus price target of C$3.85, suggesting a potential upside of 44.74%. Given Canopy Growth's stronger consensus rating and higher possible upside, analysts plainly believe Organigram is more favorable than Canopy Growth.
Summary
Canopy Growth and Organigram tied by winning 9 of the 18 factors compared between the two stocks.
Get Organigram News Delivered to You Automatically
Sign up to receive the latest news and ratings for OGI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OGI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Organigram Competitors List
Related Companies and Tools
